Integrating Human Rights into Intellectual Property Policies
Access to medicines (A2M), and particularly to essential medicines, has been recognized as a core component of the right to the highest attainable standard of health. The right to health also requires that medicines be available in sufficient quantity; accessible (including economically); acceptable (including medically); and of good quality. Moreover, the right to health has had powerful consequence in recent years, particularly in national courts, which have repeatedly articulated an enforceable state obligation to provide access to medicines.
Nonetheless, the implications of the right to health for Intellectual Property (IP) policy and R&D policy in particular have only recently begun to attract attention. This GHJP project seeks to address whether and how human rights norms and frameworks can be used to improve A2M by reducing the barriers that IP laws create. Specific outputs include:
Policy paper on Human Rights, Intellectual Property Law, & Access to Meds In 2013, GHJP produced a policy paper analyzing four possible human rights approaches: (1) the use of human rights arguments in domestic court cases that deal with intellectual property laws, (2) the articulation of norms in the United Nations (UN) human rights system, (3) the use of human rights arguments and frameworks to secure greater pharmaceutical corporate accountability, and (4) the use of health-related rights to build multilateral and regional alliances that can more effectively oppose free trade agreements (FTAs) with TRIPS-plus provisions (read the paper here). The paper provides a critical, up-to-date analysis of how human rights doctrine and arguments might be used at the international and domestic levels to challenge IP laws that undermine health.
Submission to UN Secretary-General's High Level Panel on Access to Medicines In February 2016, GHJP submitted a paper to the United Nation's Secretary-General's High Level Panel on Access to Medicines, describing the role that the High Level Panel can play in clearly articulating several implications for states and international organizations of the right to health in the context of intellectual property and innovation policy. The submission built on our 2013 policy report and was prepared in response to the High Level Panel's call for contributions on the question of "how to promote innovation and increase access to medicines, vaccines, diagnostics and related health technologies in low-, middle-, and high-income countries.
Brennan, H., Distler, R., Hinman, M., and A. Rogers. "A Human Rights Approach to Intellectual Property and Access to Medicines" Global Health Justice Partnership Working Paper (2013) (available here)
GHJP “Realizing the Right to Health in the Context of Intellectual Property Submission for the United Nations Secretary-General’s High Level Panel on Access to Medicines” (2016) (available here)
GHJP, Solomon Center for Health Law and Policy, and Program On Regulation, Therapeutics, And Law. "Submission to the Department of Trade and Industry on the Intellectual Property Consultative Framework" (2016) (available here)
Kapczynski, Amy and Sampat, Bhaven N. and Shadlen, Ken. "Trade Agreements, Patents, and Drug Prices: Continuing the Debate" Yale Law & Economics Research Paper No. 572 (2017) (available here)
Kapczynski, Amy, Bhaven N. Sampat, and Kenneth C. Shadlen. "The TPP and Drug Prices." Foreign Affairs (2017) (available here)
Kapczynski, Amy. "The Trans-Pacific Partnership — Is It Bad for Your Health?" The New England Journal of Medicine (2015) (available here)